Tyra Biosciences, Inc. (TYRA)
| Market Cap | 2.09B |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -119.95M |
| Shares Out | 59.49M |
| EPS (ttm) | -2.01 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 801,018 |
| Open | 37.00 |
| Previous Close | 36.92 |
| Day's Range | 34.56 - 38.43 |
| 52-Week Range | 8.75 - 40.65 |
| Beta | 0.96 |
| Analysts | Strong Buy |
| Price Target | 47.50 (+35.48%) |
| Earnings Date | May 6, 2026 |
About TYRA
Tyra Biosciences, Inc., a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions. Its lead product candidate is FGFR3, which is in clinical trials for the treatment of patients with metastatic urothelial carcinoma and other solid tumor... [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to 11 analysts, the average rating for TYRA stock is "Strong Buy." The 12-month stock price target is $47.5, which is an increase of 35.48% from the latest price.
News
Tyra Biosciences Announces Appointment of Habib Dable to its Board of Directors
-Seasoned biopharmaceutical leader brings deep commercial and strategic expertise to support TYRA's next phase of growth- CARLSBAD, Calif., April 17, 2026 /PRNewswire/ -- Tyra Biosciences, Inc. (Nasda...
Tyra Biosciences Transcript: TD Cowen 46th Annual Health Care Conference
Dabogratinib is advancing in three major indications—UTUC, NMIBC, and achondroplasia—with pivotal studies and key data readouts expected this year. The oral formulation, strong safety, and high unmet need position it for rapid adoption, especially in community practices.
Tyra Biosciences Reports Fourth Quarter and Full-Year 2025 Financial Results and Recent Highlights
- Launched "dabogratinib 3x3" strategy to pursue 3 late-stage clinical studies in LG-UTUC, IR NMIBC and ACH, 3 potential blockbuster indications - - Interim Ph2 data readouts on track: SURF302 expecte...
Tyra Biosciences Transcript: Oppenheimer 36th Annual Healthcare Life Sciences Conference
Multiple phase II trials are advancing for dabogratinib in FGFR3-driven diseases, with a focus on intermediate risk NMIBC, UTUC, and achondroplasia. Key data readouts are expected mid- and late-year, and the pipeline remains active with ongoing FGFR3 discovery efforts.
Tyra Biosciences Announces Poster Presentations at the 2026 ASCO® Genitourinary (GU) Cancers Symposium
CARLSBAD, Calif., Feb. 23, 2026 /PRNewswire/ -- Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target larg...
Tyra Biosciences to Participate in Upcoming Investor Conferences
CARLSBAD, Calif., Feb. 19, 2026 /PRNewswire/ -- Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target larg...
Tyra Biosciences Strengthens Leadership Team with Appointments of Bhavesh Ashar as Chief Operating Officer and Heather Faulds as Chief Regulatory Officer
CARLSBAD, Calif. , Dec. 1, 2025 /PRNewswire/ -- Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target larg...
Tyra Biosciences Transcript: Jefferies London Healthcare Conference 2025
Dabogratinib, a selective oral FGFR3 inhibitor, is advancing in phase II trials for NMIBC, upper tract urothelial carcinoma, and achondroplasia, aiming to match or exceed current efficacy benchmarks with improved safety. Key data readouts are expected in 2025, with strong physician enthusiasm and a robust financial position supporting rapid advancement.
Tyra Biosciences Announces Participation at Upcoming Investor Events
CARLSBAD, Calif. , Nov. 12, 2025 /PRNewswire/ -- Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target lar...
Tyra Biosciences Reports Third Quarter 2025 Financial Results and Highlights
- Dosed first patients with dabogratinib in BEACH301 and SURF302; interim results from both studies expected in 2026 - - Expanded development of dabogratinib into low-grade upper tract urothelial carc...
Tyra Biosciences Transcript: H.C. Wainwright 27th Annual Global Investment Conference
A highly selective oral FGFR3 inhibitor is advancing in phase 2 trials for NMIBC and ACH, aiming to address significant unmet needs with a differentiated safety and efficacy profile. The company is positioned to capture large market opportunities by offering a convenient, best-in-class therapy.
Tyra Biosciences Transcript: H.C.Wainwright @ Home Fireside Chat
Two phase II programs for a selective FGFR3 inhibitor are advancing in NMIBC and achondroplasia, both prioritized due to strong scientific rationale and large patient populations. The oral therapy offers a favorable safety profile and convenience, with initial data expected next year and a cash runway through 2027.
Tyra Biosciences Announces First Child Dosed in BEACH301, its Phase 2 Study for Dabogratinib (TYRA-300) in Pediatric Achondroplasia
-Dabogratinib is the only oral FGFR3-selective inhibitor in clinical development for achondroplasia- -Initial results from safety sentinel cohort expected in 2H 2026- CARLSBAD, Calif. , Aug. 21, 2025 ...
Tyra Biosciences Reports Second Quarter 2025 Financial Results and Highlights
- Dosed first patient in SURF302 for intermediate risk non-muscle invasive bladder cancer (IR NMIBC) - - Cash, cash equivalents, and marketable securities of $296.3 million at Q2 2025; runway through ...
Tyra Biosciences Transcript: Status Update
TYRA-300, a highly selective FGFR3 inhibitor, is advancing in both skeletal dysplasia and oncology indications, aiming for superior efficacy and safety over current therapies. The BEACH301 trial in achondroplasia targets 8–8.5 cm/year growth, with initial safety and efficacy data expected next year. TYRA-300 also shows strong potential in oncology with reduced toxicity.
Tyra Biosciences Announces Fireside Chat on Achondroplasia and Growth Disorders at UBS Biotech Management Live Call Series
CARLSBAD, Calif. , July 21, 2025 /PRNewswire/ -- Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target lar...
Tyra Biosciences Announces Late-Breaking Poster Presentation on TYRA-300 Preclinical Results at ENDO 2025
CARLSBAD, Calif. , July 8, 2025 /PRNewswire/ -- Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target larg...
Tyra Biosciences Doses First Patient in Phase 2 Study of TYRA-300 in Low-Grade Intermediate Risk Non-Muscle Invasive Bladder Cancer (SURF302)
-TYRA-300 is the only orally administered investigational agent in clinical development for IR NMIBC- -Initial 3-month complete response (CR) data expected to be reported in 1H 2026- CARLSBAD, Calif. ...
Tyra Biosciences Transcript: BofA Securities 2025 Healthcare Conference
The conference highlighted a differentiated FGFR3 inhibitor platform with promising early clinical results in NMIBC and achondroplasia, aiming for superior efficacy and safety over current therapies. Strategic focus is on key phase two trials, with strong financial positioning through 2027.
Tyra Biosciences to Participate at Upcoming Investor Conferences
CARLSBAD, Calif. , May 12, 2025 /PRNewswire/ -- Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target larg...
Tyra Biosciences Reports First Quarter 2025 Financial Results and Highlights
- BEACH301 study of TYRA-300 for Pediatric Achondroplasia (ACH) Open for Enrollment - - Initiated patient dosing in SURF431 study of TYRA-430 for hepatocellular carcinoma (HCC) - - Cash, cash equivale...
Tyra Biosciences Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights
- Three INDs cleared by US FDA for TYRA's proprietary precision small molecules - - TYRA-300 to be evaluated in three Phase 2 studies: SURF302 for Intermediate Risk Non-Muscle Invasive Bladder Cancer ...
Tyra Biosciences Transcript: TD Cowen 45th Annual Healthcare Conference
TYRA-300, a selective FGFR3 inhibitor, shows strong efficacy and a favorable safety profile in urothelial carcinoma and achondroplasia, with phase II trials underway in NMIBC and ACH. Early data readouts are expected by early next year, with plans to expand into additional skeletal dysplasias.
Tyra Biosciences Transcript: Oppenheimer 35th Annual Healthcare Life Sciences Conference (Virtual) 2025
TYRA-300 shows strong efficacy and safety in urothelial cancer and NMIBC, with lower toxicity than competitors and promising market potential. Achondroplasia and related growth disorders represent significant expansion opportunities, and a novel FGFR3/4 inhibitor for liver cancer is entering clinical trials.
Tyra Biosciences to Present at Upcoming Investor Conferences
CARLSBAD, Calif. , Feb. 11, 2025 /PRNewswire/ -- Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target lar...